About Us > Overview
NeXeption builds innovative companies by bringing together pharmaceutical product opportunities, management expertise and the necessary funding to rapidly advance therapies through clinical and regulatory milestones.
Our unique business model creates, funds and manages independent operating companies focused solely on maximizing the value of each potential opportunity. We target programs that address unmet medical needs and have a high technical probability of success.
NeXeption’s experienced team of pharmaceutical and biotechnology executives has a proven track record of identifying, developing, registering and commercializing new products. Our founding partners have experience in a broad array of functional areas and therapeutic sectors, with a focus on both small molecules and biologics, from candidate selection through Phase IV development.
FOR PHARMA COMPANIES, NeXeption provides an alternative pipeline development path for non-progressing assets or science. We look for new drug candidates with validated targets and evidence of differentiation. We then form and fund individual companies to focus on the development of these programs, advancing them through regulatory milestones to the point of commercialization or strategic partnership.
FOR INVENTORS OR ENTREPRENEURS, the experienced NeXeption management team offers the appropriate resources and access to capital to advance assets from concept through commercialization. We can help build out a full multidisciplinary team to accelerate as well as optimize the development and commercialization of programs.
FOR INVESTORS, our experienced team of pharmaceutical and biotechnology executives has a proven track record of identifying, developing, registering and commercializing new products. To date, four companies formed by members of the management team have been successfully partnered, generating high returns for investors.
NeXeption has an important advantage in its fully-dedicated, shared management team, which includes representation from key disciplines -- clinical, R&D, regulatory, BD, commercial, legal and project management -- that can be utilized across companies. This unique asset provides NeXeption companies with access to a multidisciplinary senior management team without the high price tag typically attached. Additionally, NeXeption already has overhead and operating systems in place, ensuring the majority of funding goes toward product development.
Our current portfolio of companies includes Aclaris Therapeutics, Inc. a specialty pharmaceutical company founded in 2012. Aclaris is focused on identifying, developing and commercializing innovative and differentiated topical drugs to address significant unmet needs in dermatology. In 2014, we launched Alexar Therapeutics, Inc., a specialty pharmaceutical company developing topical and systemic therapies based on Liver X Receptor (LXR) modulators. The initial focus for Alexar will be on developing its lead compound for the treatment of various dermatological conditions. In 2015, we formed Velicept to merge with privately held AltheRx Pharmaceuticals to advance the development of solabegron, a highly differentiated beta 3-adrenoceptor agonist for the treatment of over active bladder. All three companies are headquartered in Malvern, PA. To learn more visit www.Aclaristx.com or www.Alexartx.com.
NeXeption is actively seeking additional development-ready assets across a broad range of therapeutic areas. For more information, contact us.
The NeXeption management companies include NST, LLC (and its wholly-owned subsidiary NST Consulting, LLC), NeXeption, LLC and NeXeption II, LLC. NST Consulting, LLC provides the majority of the day-to-day management services to our portfolio of operating companies.